Skip to main content
HEPA
OTC Life Sciences

Hepion Pharma 2025 10-K

feedReported by Wiseek News
Sentiment info
Negative
Importance info
9
Price
$0.045
Mkt Cap
$522.914K
52W Low
$0.033
52W High
$267.5
Market data snapshot near publication time

summarizeSummary

Hepion Pharmaceuticals 2025 10-K , , $8.28M , $(0.88) . 2024 ASCEND-NASH , , 3 8-K , , . , , , , , , , , , , , .

在该公告发布时，HEPA的交易价格为$0.05，交易所为OTC，所属行业为Life Sciences，市值约为$52.3万。 52周交易区间为$0.03至$267.50。 这则新闻被评估为消极市场情绪，重要性评分为9/10。 来源：Wiseek News。

show_chartPrice Chart

Share this article

Copied!

feed HEPA - Latest Insights

HEPA
Apr 14, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
8
Hepion Pharmaceuticals Finalizes CEO Separation Agreement, Discloses $255K Payout Amidst Going Concern Warning
Sentiment: Negative
View Wiseek Article
HEPA
Mar 18, 2026, 4:15 PM EDT
Filing Type: 8-K
Importance Score:
9
Hepion Pharmaceuticals CEO Resigns Amidst Financial Distress; Interim CEO and New Directors Appointed
Sentiment: Negative
View Wiseek Article
HEPA
Mar 12, 2026, 6:15 AM EDT
Source: Wiseek News
Importance Score:
9
Hepion Pharma's 2025 10-K Reveals Zero Revenue, $8.28M Net Loss, Clinical Trial Wind-Down
Sentiment: Negative
View Wiseek Article
HEPA
Mar 11, 2026, 9:43 PM EDT
Filing Type: 10-K
Importance Score:
9
Hepion Pharmaceuticals Faces Imminent Cash Shortage, Nasdaq Delisting, and Material Weaknesses in Annual Report
Sentiment: Negative
View Wiseek Article
HEPA
Mar 03, 2026, 8:11 AM EST
Filing Type: 8-K
Importance Score:
8
Hepion Pharmaceuticals Licenses Novel ctRNA Assay, Pivoting to Liquid Biopsy Diagnostics
Sentiment: Positive
View Wiseek Article
HEPA
Jan 15, 2026, 4:15 PM EST
Filing Type: 8-K
Importance Score:
7
Hepion Pharmaceuticals Appoints Dr. Kaouthar Lbiati as CEO with Compensation Tied to $3M Equity Financing
Sentiment: Neutral
View Wiseek Article